By admin Entinostat, a histone deacetylase inhibitor (HDACi), has shown promise as a combinatorial therapeutic for rhabdomyosarcoma (RMS), a rare and aggressive childhood cancer. Here’s a summary of its potential:
1. Enhances chemotherapy: Entinostat increases the sensitivity of RMS cells to conventional chemotherapy agents, such as vincristine and doxorubicin.
2. Inhibits tumor growth: Entinostat reduces RMS tumor growth by inducing cell cycle arrest, apoptosis, and autophagy.
3. Targets cancer stem cells: Entinostat targets and eliminates RMS cancer stem cells, which are responsible for tumor initiation and recurrence.
4. Combination with immunotherapy: Entinostat enhances the efficacy of immunotherapies, such as checkpoint inhibitors, by increasing tumor antigen presentation and immune cell infiltration.
5. Overcomes drug resistance: Entinostat can overcome resistance to chemotherapy and targeted therapies in RMS cells.
6. Synergistic effects with other HDACis: Combining entinostat with other HDACis or epigenetic modulators may enhance its anti-tumor effects.
7. Potential biomarkers: Entinostat’s efficacy may be predicted by biomarkers such as HDAC expression levels, histone acetylation status, or gene expression profiles.
Ongoing and future clinical trials will further investigate entinostat’s safety and efficacy as a combinatorial therapeutic for RMS.